Zenas BioPharma is a clinical-stage biopharmaceutical company that develops and commercializes transformative immunology-based therapies. Its product Obexelimab, is a bifunctional monoclonal antibody engineered to mimic the natural antigen-antibody complex for the inhibition of B cells.